Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Berlin, Germany, and U.S.A., August 7, 2013 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first half and second quarter of 2013 ending June 30.
- Revenue in Q2 2013 increased by 120% to EUR 343 thousand compared to Q2 2012
- Operating costs decreased by 44% to EUR 2,098 thousand over Q2 2012
- EBIT in Q2 improved by 53% to EUR -1,607 thousand compared to Q2 2012
- Net cash flow in H1 2013 positive due to successful capital increase in January
- Level 1 ADR program established
Attached, please find a pdf version of this announcement.
Conference call for press and analysts
The full 6-Months Financial Report 2013 can be obtained from Epigenomics’ website at: http://www.epigenomics.com/en/news-investors/investors/financial-reports/2013.html
Epigenomics’ management will host a conference call with web presentation at 3pm CET/9am ET today, Wednesday, August 7th, 2013. The conference call will be held in English.
The dial-in numbers for the conference call are:
Dial-in number (within Germany): + 49 69 247 501 895
Dial-in number (within the UK): +44 203 367 9216
Dial-in number (within the U.S.): +1 408 916 9838
Participants are kindly requested to dial in 10 minutes prior to the start of the call.
The presentation accompanying the conference call and dial-in details for the web presentation will be available on Epigenomics’ website: http://www.epigenomics.com/en/news-investors.html
Both an audio replay of the conference call and a transcript of the conference call will be provided on Epigenomics’ website subsequently: http://www.epigenomics.com/en/news-investors.html
Please do not hesitate to come back to us for further questions.
Caroline Bergmann
MC Services AG
Schubertstr. 10
D-80336 München
phone: +49 89 210 228 20
mobile: +49 175 2624256
fax: +49 89 210 228 88
email: caroline.bergmann@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.
Berlin, Germany, and U.S.A., August 7, 2013 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first half and second quarter of 2013 ending June 30.
- Revenue in Q2 2013 increased by 120% to EUR 343 thousand compared to Q2 2012
- Operating costs decreased by 44% to EUR 2,098 thousand over Q2 2012
- EBIT in Q2 improved by 53% to EUR -1,607 thousand compared to Q2 2012
- Net cash flow in H1 2013 positive due to successful capital increase in January
- Level 1 ADR program established
Attached, please find a pdf version of this announcement.
Conference call for press and analysts
The full 6-Months Financial Report 2013 can be obtained from Epigenomics’ website at: http://www.epigenomics.com/en/news-investors/investors/financial-reports/2013.html
Epigenomics’ management will host a conference call with web presentation at 3pm CET/9am ET today, Wednesday, August 7th, 2013. The conference call will be held in English.
The dial-in numbers for the conference call are:
Dial-in number (within Germany): + 49 69 247 501 895
Dial-in number (within the UK): +44 203 367 9216
Dial-in number (within the U.S.): +1 408 916 9838
Participants are kindly requested to dial in 10 minutes prior to the start of the call.
The presentation accompanying the conference call and dial-in details for the web presentation will be available on Epigenomics’ website: http://www.epigenomics.com/en/news-investors.html
Both an audio replay of the conference call and a transcript of the conference call will be provided on Epigenomics’ website subsequently: http://www.epigenomics.com/en/news-investors.html
Please do not hesitate to come back to us for further questions.
Caroline Bergmann
MC Services AG
Schubertstr. 10
D-80336 München
phone: +49 89 210 228 20
mobile: +49 175 2624256
fax: +49 89 210 228 88
email: caroline.bergmann@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.
